CRF: Treatment for IBS/Info
- Hi Everyone,
I thought this would be of some interest to you all.
Cynthia, Taffy, Samuel
Tummy trouble? Try taming it with peppermint oil.
If you're bothered by irritable bowel syndrome (IBS), which affects 20%
of Americans--twice as many women as men--give peppermint oil a try.
Long considered a folk remedy, several studies have shown that IBS
sufferers who took peppermint oil capsules reduced their symptoms
significantly compared to patients who took a placebo. Researchers
believe the oil relaxes the smooth muscle in the lining of the
intestine, which reduces muscle spasms.
The recommended dose is 90 milligrams three times per day, preferably
with a meal. Because peppermint oil can trigger acid reflux, make sure
that you take the coated-capsule form. This will reduce your chances of
Irritable bowel syndrome (IBS) is a condition marked by alternating
diarrhea and constipation, pain, bloating, and an unnerving sense of
urgency when nature calls. IBS diagnosis can be frustrating, generally
coming only after other problems, such as cancer and colon obstruction,
have been ruled out. Because the condition is exacerbated by stress,
doctors used to routinely dismiss it as psychological. Although many
cases are mild, the discomfort of IBS and the fear of humiliation can
keep sufferers housebound. After colds, IBS is the second most common
reason for missed work in the U.S.
Enteric-coated peppermint-oil capsules in the treatment of irritable
bowel syndrome: a prospective, randomized trial.
Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK
Department of Internal Medicine, Taichung Veterans
General Hospital, Taiwan.
To determine the efficacy and tolerability of an enteric-coated
peppermint-oil formulation (Colpermin), we conducted a prospective,
randomized, double-blind, placebo-controlled clinical study in 110
outpatients (66 men/44 women; 18-70 years of age) with symptoms of
irritable bowel syndrome. Patients took one capsule (Colpermin or
placebo) three to four times daily, 15-30 min before meals, for 1 month.
Fifty-two patients on Colpermin and 49 on placebo completed the study.
Forty-one patients on Colpermin (79%) experienced an alleviation of the
severity of abdominal pain (29 were pain-free); 43 (83%) had less
abdominal distension, 43 (83%) had reduced stool frequency, 38 (73%) had
fewer borborygmi, and 41 (79%) less flatulence. Corresponding figures
for the placebo group were: 21 patients (43%) with reduced pain (4 were
pain-free), 14 (29%) with reduced distension, 16 (32%) with reduced
stool frequency, 15 (31%) with fewer borborygmi, and 11 (22%) with less
flatulence. Symptom improvements after Colpermin were significantly
better than after placebo (P < 0.05; Mann-Whitney U-test). One patient
on Colpermin experienced heartburn (because of chewing the capsules) and
one developed a mild transient skin rash. There were no significant
changes in liver function test results. Thus, in this trial, Colpermin
was effective and well tolerated.
Randomized controlled trial
PMID: 9430014, UI: 98091849
Effects of peppermint oil and caraway oil on gastroduodenal motility.
Micklefield GH, Greving I, May B
Department of Internal Medicine,
Ferdinand-Sauerbruch-Klinikum, University Hospital Witten/Herdecke,
Teaching Hospital of the Heinrich-Heine-University/Dusseldorf,
Arrenberger Str. 20, 42117 Wuppertal, Germany.
The effect of enteric-coated (Enteroplant) and non-enteric-coated
preparations containing a peppermint-caraway oil combination with 90 mg
peppermint oil and 50 mg caraway oil was studied on gastroduodenal
motility with stationary manometry in six healthy volunteers. The
results showed that: (1) both enteric-coated and non-enteric-coated
preparations have effects on the migrating motor complex (MMC); (2)
mainly a decrease in the number of contractions and contraction
amplitudes is seen during the various phases of the MMC; (3)
non-enteric-coated preparations have their effects mainly during the
first MMC after administration; (4) enteric-coated preparations have
their effects temporally delayed during the second MMC after
administration. In conclusion, enteric-coated and non-enteric-coated
peppermint-caraway oil combinations are safe preparations, acting
locally to cause smooth muscle relaxation. Copyright 2000 John Wiley &
Controlled clinical trial
PMID: 10641042, UI: 20109240
[Peppermint oil-caraway oil fixed combination in non-ulcer
dyspepsia--comparison of the effects of enteric preparations].
[Article in German]
Freise J, Kohler S
Evangelisches Krankenhaus, Muhlheim/Ruhr, Germany.
223 patients with non-ulcer dyspepsia (dysmotility type dyspepsia or
essential/idiopathic dyspepsia, also in combination with irritable bowel
syndrome) were included in a prospective, randomised, reference- and
double-blind controlled multicentre trial to compare two different
preparations of a fixed combination of peppermint oil and caraway oil.
The aim of the trial was to evaluate the equivalence of the efficacy and
tolerability of these two preparations. The test formulation consisted
of the drug combination in an enteric coated capsule containing 90 mg
peppermint oil and 50 mg caraway oil, while an enteric soluble
formulation containing 36 mg peppermint oil and 20 mg caraway oil was
used as the reference. The main target item defined was the "difference
in pain intensity between the beginning and the end of therapy",
measured by the patient on a visual analogue scale (0 = no pain, 10 =
extremely strong pain). In 213 patients (n = 108 on the test
preparation, n = 105 on the reference preparation) with mean pain
intensity baseline measurements of 6.1 points in the test preparation
group and 5.9 points in the reference group a statistically significant
decline in pain intensity was observed in the two groups
(-3.6 resP. -3.3 points; p < 0.001; two-sided one-sample t-test).
Equivalent efficacy of both preparations was demonstrated (p < 0.001;
one-sided t-test for equivalence). With respect to concomitant
variables, the results in both groups were also similar. Regarding "pain
frequency", the efficacy of the test preparation was significantly
better (p = 0.04; two-sided t-test for difference). Both preparations
were well tolerated. Despite the higher dose, the adverse event
"eructation with peppermint taste" was less frequent in the group
treated with the test formulation, due to the enteric coated capsule
Randomized controlled trial
PMID: 10192108, UI: 99207832
This is the only link I could find, your will have to do a search
there to find these articles.
site at http://www.ncbi.nlm.nih.gov